|
Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BIND Biosciences; Myriad Genetics |
Research Funding - Abbvie; Genentech; PharmaMar |
Travel, Accommodations, Expenses - Genentech; Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bio-Rad; Clovis Oncology |
Patents, Royalties, Other Intellectual Property - CfDNA genotyping, pending |
Travel, Accommodations, Expenses - Bio-Rad |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Enlight Biosciences; Ophthotech; SynDevRx; XTuit Pharmaceuticals |
Consulting or Advisory Role - Ophthotech; Sun Pharma; SynDevRx; XTuit Pharmaceuticals |
Research Funding - Merrimack; Roche/Genentech |
|
|
|
Consulting or Advisory Role - Genentech/Roche; Novartis; Verastem |
Research Funding - Genentech/Roche (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche |
|
|
No Relationships to Disclose |